超级碰在线-超级碰碰永久免费视频播放-超级碰碰碰免费视频播放-超级碰碰碰免费视频-亚洲国产99在线精品一区69堂-亚洲高清资源在线观看

美國Pathwork Diagnostics  
Pathwork Diagnostics公司是一家從事腫瘤疾病分子診斷技術研發的企業，該公司宣布在一輪融資中獲得來自Abingworth總額為2000萬美元的投資。據悉，在募資消息宣布前不久，Pathwork Diagnostics公司已經得到了食品和藥物管理局（FDA）關于對一些不確定病原型腫瘤進行組織病原測試的許可，這些不確定病原腫瘤包括那些低分化，未分化和轉移性腫瘤。

Pathwork Diagnostics, Inc., is a privately held company in Redwood City, CA, that develops and commercializes innovative, high-value molecular diagnostics for oncology. The company’s Pathwork? Tissue of Origin Test is a microarray-based gene expression test that aids in identifying challenging tumors, including poorly differentiated, undifferentiated, and metastatic cancers. It is the only FDA-cleared and Medicare-covered molecular test of its kind. The company provides the Tissue of Origin Test through its CLIA-certified, CAP-accredited laboratory.
In the U.S., approximately 150,000 newly diagnosed cancer patients may have a tumor that is metastatic, undifferentiated, or poorly differentiated, and often difficult to diagnose. These patients may benefit from the Tissue of Origin Test, because knowing the site of origin for these challenging tumors may lead to more effective treatment.